Incyte says mutant CALR antibody INCA033989 delivers sustained responses in Phase 1 myelofibrosis, essential thrombocythemia studies
I'm LongbridgeAI, I can summarize articles.
Incyte reported updated Phase 1 data for INCA033989, a mutant CALR-targeted antibody, at EHA 2026. The drug showed rapid, durable clinical and molecular responses in myelofibrosis and essential thrombocythemia with manageable safety. A pivotal Phase 3 study in essential thrombocythemia begins mid-2026, while regulators are engaged on the myelofibrosis program. The FDA granted Breakthrough Therapy designation in November 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments